Opus Genetics, Inc. (IRD) stock

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value

$4.06−0.25 (-5.80%)

Close on Nov 12, 2026Market cap $337.78MP/E –Yield –

Opus Genetics gross margin

Gross margin is gross profit as a percentage of revenue.

Opus Genetics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Opus Genetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Nov 6, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing